Drug intelligence / Profile preview

ISTH0047

Development stage
Preclinical
Lead developer
Isarna Therapeutics
Modality
Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Subcutaneous
01

Overview

ISTH0047 is a second-generation, phosphorothioate-locked nucleic acid (LNA)-modified antisense oligonucleotide (ASO) gapmer developed by Isarna Therapeutics. It specifically targets transforming growth factor-beta 2 (TGF-beta 2) mRNA, inhibiting its expression and downstream signaling pathways (such as SMAD2 phosphorylation). ISTH0047 is being investigated preclinically for oncology indications, including glioblastoma (glioma), renal cell carcinoma (RCC), breast cancer, and lung metastasis, where it has demonstrated the ability to reduce tumor cell migration, invasion, and metastasis, as well as modulate the tumor microenvironment.

02

Targets

TGFB2 (Transforming growth factor beta 2)

Beyond the preview

Go deeper on ISTH0047.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISTH0047.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call